Crisaborole

Short Description:

API’s Name CAS No. US DMF Patent Expiry Date (US) Current status
Crisaborole 906673-24-3  37356 Jun.29, 2029 Commercial Production

 

[Indication] 

It is a phosphodiesterase 4 inhibitor indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.


Product Detail

Product Tags


  • Previous:
  • Next:

  • Write your message here and send it to us